Bronchopulmonary Dysplasia Pipeline 2024: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Chiesi Farmaceutici S.p.A., AyuVis Research, Airway Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Bronchopulmonary Dysplasia pipeline constitutes 12+ key companies continuously working towards developing 12+ Bronchopulmonary Dysplasia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Bronchopulmonary Dysplasia Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Bronchopulmonary Dysplasia Market.

The Bronchopulmonary Dysplasia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Bronchopulmonary Dysplasia Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Bronchopulmonary Dysplasia treatment therapies with a considerable amount of success over the years.

*
Bronchopulmonary Dysplasia companies working in the treatment market are Chiesi Farmaceutici S.p.A., AyuVis Research, Airway Therapeutics, Inc, Meridigen Biotechnology, Medipost Co., Ltd., Oak Hill Bio Ltd., Mallinckrodt, The Emmes Company, LLC, Medipost Co Ltd., and others, are developing therapies for the Bronchopulmonary Dysplasia treatment

*
Emerging Bronchopulmonary Dysplasia therapies in the different phases of clinical trials are- OHB-607, AVR-48, AT-100, UMC119-01, Pneumostem, OHB-607, INOmax, Furosemide Cohort 1, Inhaled Nitric Oxide, PNEUMOSTEM Registered , Curosurf, and others are expected to have a significant impact on the Bronchopulmonary Dysplasia market in the coming years.

*
In October 2024, Airway Therapeutics, Inc. (Airway), a biopharmaceutical company focused on developing a novel class of biologics to disrupt the cycle of injury and inflammation in patients with respiratory and inflammatory conditions, has announced plans to begin a multinational Phase 3 clinical trial in December 2024. The trial will evaluate zelpultide alfa (rhSP-D) for preventing bronchopulmonary dysplasia (BPD) and minimizing the associated lung damage in preterm infants.

*
In April 2024, EXO Biologics aims to obtain conditional market approval from the European Medicines Agency (EMA) for its bronchopulmonary dysplasia (BPD) preventative, EXOB-001, in preterm newborns, pending the success of its Phase I/II trial.

*
In January 2024, Chiesi Farmaceutici SpA ("Chiesi Group"), a globally recognized biopharmaceuticals and healthcare organization with a focus on research, and Oak Hill Bio, a clinical-stage company specializing in neonatology and rare disease therapeutics, have officially entered into a License and Development Agreement. This collaboration aims to develop, produce, and bring to market OHB-607, an investigational drug designed to address complications associated with extremely premature birth. OHB-607 comprises a recombinant form of insulin-like growth factor-1 (IGF-1) combined with its binding protein, formulated to prevent bronchopulmonary dysplasia in preterm infants. IGF-1 plays a crucial role in fetal organ growth and development, with mothers being the primary source of this growth factor until approximately 30 weeks gestational age.

Bronchopulmonary Dysplasia Overview

Bronchopulmonary dysplasia (BPD) is a chronic lung disease that primarily affects premature infants, especially those born very early, usually before 28 weeks of gestation. This condition is a consequence of lung injury and inflammation, often resulting from the use of mechanical ventilation and oxygen therapy, which are common interventions in the care of premature infants with respiratory distress syndrome.

Get a Free Sample PDF Report to know more about Bronchopulmonary Dysplasia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-pipeline-insight [https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Bronchopulmonary Dysplasia Drugs Under Different Phases of Clinical Development Include:

*
OHB-607: Chiesi Farmaceutici S.p.A.

*
AVR-48: AyuVis Research

*
AT-100: Airway Therapeutics, Inc

*
UMC119-01: Meridigen Biotechnology

*
Pneumostem: Medipost Co., Ltd.

*
OHB-607: Oak Hill Bio Ltd.

*
INOmax: Mallinckrodt

*
Furosemide Cohort 1: The Emmes Company, LLC

*
Inhaled Nitric Oxide: Mallinckrodt

*
PNEUMOSTEM Registered : Medipost Co Ltd.

*
Curosurf: Chiesi Farmaceutici S.p.A.

Bronchopulmonary Dysplasia Route of Administration

Bronchopulmonary Dysplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Inhalation

*
Inhalation/Intravenous/Oral

*
Intranasal

*
Intravenous

*
Intravenous/ Subcutaneous

*
NA

*
Oral

*
Oral/intranasal/subcutaneous

*
Parenteral

*
Subcutaneous

Bronchopulmonary Dysplasia Molecule Type

Bronchopulmonary Dysplasia Products have been categorized under various Molecule types, such as

*
Antibody

*
Antisense oligonucleotides

*
Immunotherapy

*
Monoclonal antibody

*
Peptides

*
Protein

*
Recombinant protein

*
Small molecule

*
Stem Cell

*
Vaccine

Bronchopulmonary Dysplasia Pipeline Therapeutics Assessment

*
Bronchopulmonary Dysplasia Assessment by Product Type

*
Bronchopulmonary Dysplasia By Stage and Product Type

*
Bronchopulmonary Dysplasia Assessment by Route of Administration

*
Bronchopulmonary Dysplasia By Stage and Route of Administration

*
Bronchopulmonary Dysplasia Assessment by Molecule Type

*
Bronchopulmonary Dysplasia by Stage and Molecule Type

DelveInsight's Bronchopulmonary Dysplasia Report covers around 12+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Bronchopulmonary Dysplasia product details are provided in the report. Download the Bronchopulmonary Dysplasia pipeline report to learn more about the emerging Bronchopulmonary Dysplasia therapies [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Bronchopulmonary Dysplasia Pipeline Analysis:

The Bronchopulmonary Dysplasia pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Bronchopulmonary Dysplasia with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bronchopulmonary Dysplasia Treatment.

*
Bronchopulmonary Dysplasia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Bronchopulmonary Dysplasia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bronchopulmonary Dysplasia market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Bronchopulmonary Dysplasia drugs and therapies [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Bronchopulmonary Dysplasia Pipeline Market Drivers

*
Increased Research and Development Activities, new and developed Robust Pipeline are some of the important factors that are fueling the Bronchopulmonary Dysplasia Market.

Bronchopulmonary Dysplasia Pipeline Market Barriers

*
However, complications with available treatment options, no Bronchopulmonary Dysplasia approved therapy, lack of a reliable methods for identifying pediatric patients at risk and other factors are creating obstacles in the Bronchopulmonary Dysplasia Market growth.

Scope of Bronchopulmonary Dysplasia Pipeline Drug Insight

*
Coverage: Global

*
Key Bronchopulmonary Dysplasia Companies: Chiesi Farmaceutici S.p.A., AyuVis Research, Airway Therapeutics, Inc, Meridigen Biotechnology, Medipost Co., Ltd., Oak Hill Bio Ltd., Mallinckrodt, The Emmes Company, LLC, Medipost Co Ltd., and others

*
Key Bronchopulmonary Dysplasia Therapies: OHB-607, AVR-48, AT-100, UMC119-01, Pneumostem, OHB-607, INOmax, Furosemide Cohort 1, Inhaled Nitric Oxide, PNEUMOSTEM Registered , Curosurf, and others

*
Bronchopulmonary Dysplasia Therapeutic Assessment: Bronchopulmonary Dysplasia current marketed and Bronchopulmonary Dysplasia emerging therapies

*
Bronchopulmonary Dysplasia Market Dynamics: Bronchopulmonary Dysplasia market drivers and Bronchopulmonary Dysplasia market barriers

Request for Sample PDF Report for Bronchopulmonary Dysplasia Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Bronchopulmonary Dysplasia Report Introduction

2. Bronchopulmonary Dysplasia Executive Summary

3. Bronchopulmonary Dysplasia Overview

4. Bronchopulmonary Dysplasia- Analytical Perspective In-depth Commercial Assessment

5. Bronchopulmonary Dysplasia Pipeline Therapeutics

6. Bronchopulmonary Dysplasia Late Stage Products (Phase II/III)

7. Bronchopulmonary Dysplasia Mid Stage Products (Phase II)

8. Bronchopulmonary Dysplasia Early Stage Products (Phase I)

9. Bronchopulmonary Dysplasia Preclinical Stage Products

10. Bronchopulmonary Dysplasia Therapeutics Assessment

11. Bronchopulmonary Dysplasia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Bronchopulmonary Dysplasia Key Companies

14. Bronchopulmonary Dysplasia Key Products

15. Bronchopulmonary Dysplasia Unmet Needs

16 . Bronchopulmonary Dysplasia Market Drivers and Barriers

17. Bronchopulmonary Dysplasia Future Perspectives and Conclusion

18. Bronchopulmonary Dysplasia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bronchopulmonary-dysplasia-pipeline-2024-latest-fda-approvals-clinical-trials-and-emerging-therapies-assessment-by-delveinsight-chiesi-farmaceutici-spa-ayuvis-research-airway-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.